CALM, CSA, DCTH - CRWESelect.com Stock News! Cal-Maine Foods, Cogdell Spencer, Delcath Systems (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) December 27, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27938/stock-alerts/calm-csa-dcth-crweselectcom-stock-news-cal-maine-foods-cogdell-spencer-delcath-systems-video-included-inside/

Cal-Maine Foods, Inc. (NASDAQ:CALM)

CALM announced today results for the second quarter and six months ended November 26, 2011. Net sales for the second quarter of fiscal 2012 were $290.4 million compared with net sales of $234.5 million for the same quarter of fiscal 2011. The Company reported net income of $23.3 million, or $0.97 per basic share, for the second quarter of fiscal 2012 compared with net income of $15.2 million, or $0.64 per basic share, for the second quarter of fiscal 2011. For the first six months of fiscal 2012, net sales were $534.2 million compared with net sales of $424.9 million for the prior-year period. The Company reported net income of $26.4 million, or $1.11 per basic share, for the first half of fiscal 2012 compared with net income of $19.9 million, or $0.84 per basic share, for the year-earlier period.

CALM is primarily engaged in the production, grading, packing and sale of fresh shell eggs, including conventional, cage-free, organic and nutritionally-enhanced eggs. The Company, which is headquartered in Jackson, Mississippi, is the largest producer and distributor of fresh shell eggs in the United States and sells the majority of its shell eggs in approximately 29 states across the southwestern, southeastern, mid-western and mid-Atlantic regions of the United States.

For more information about CALM please visit http://www.calmainefoods.com/

****

Cogdell Spencer, Inc. (NYSE:CSA)

Ventas, Inc. and CSA announced today that the Boards of Directors of both companies have approved a definitive agreement under which Ventas will acquire Cogdell and its 72 high quality medical office buildings (“MOBs”) in an all-cash transaction. At closing, Ventas’s investment, including its share of debt, is expected to approximate $760 million to $770 million, before anticipated transaction expenses.

Charlotte-based CSA, healthcare's preferred real estate partner, is a real estate investment trust ("REIT") focused on planning, owning, developing, constructing, and managing medical facilities. Through strategically managed, customized facilities, we help our clients deliver superior healthcare.

For more information about CSA please visit http://www.cogdellspencer.com

****

Delcath Systems, Inc. (NASDAQ:DCTH)

DCTH announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT® Delivery system with Johann Wolfgang Goethe University Hospital (J.W. Goethe), a premier European cancer treatment and research center located in Frankfurt, Germany . Under the terms of the agreement, the Company will provide J.W. Goethe with logistics and clinical training support in the performance of chemosaturation therapy using the CHEMOSAT system. The Company expects to conduct the training using the Generation Two version of the CHEMOSAT system, pending CE Mark approval, and for training to begin at the J.W. Goethe University Hospital in February 2012 .

DCTH is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011 . The Company has not yet received FDA approval for commercial sale of its system in the United States .

For more information about DCTH please visit http://www.delcath.com/

To read the full article visit URL http://crweselect.com/27938/stock-alerts/calm-csa-dcth-crweselectcom-stock-news-cal-maine-foods-cogdell-spencer-delcath-systems-video-included-inside/

*****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

CALMcrweselect1227
CSAcrweselect1227
DCTHcrweselect1227

calm     Cogdell Spencer     CSA     DCTH     Delcath Hepatic CHEMOSAT     Delcath Systems     ventas